Table 3.
Summary of in Vivo Activity of M6620, Cisplatin, and the Combination of M6620 and cisplatin
| Line | Tumor Type | Treatment Group | Median Time to Event | P-value | EFS T/C | Median RTV/CD45 at End of Study | Tumor Volume T/C | EFS Activity | Response |
|---|---|---|---|---|---|---|---|---|---|
| BT-29* | Rhabdoid | Cisplatin | 23.5 | 0.004 | 1.5 | >4 | 0.69 | Low | PD1 |
| BT-29* | Rhabdoid | M6620 | 23.6 | 0.019 | 1.5 | >4 | 0.69 | Low | PD1 |
| BT-29* | Rhabdoid | Combo | 36.8 | <0.001 | 2.3 | >4 | 0.48 | Int | PD2 |
| KT-12 | Rhabdoid | Cisplatin | 20.4 | <0.001 | 1.7 | >4 | 0.48 | Low | PD2 |
| KT-12 | Rhabdoid | M6620 | 13.3 | 0.858 | 1.1 | >4 | 0.83 | Low | PD1 |
| KT-12 | Rhabdoid | Combo | 19.8 | 0.006 | 1.7 | >4 | 0.46 | Low | PD2 |
| KT-10 | Wilms | Cisplatin | > EP | <0.001 | > 9.1 | 0 | 0.01 | High | MCR |
| KT-10 | Wilms | M6620 | 9.3 | 0.141 | 0.9 | >4 | 1.12 | Low | PD1 |
| KT-10 | Wilms | Combo | > EP | <0.001 | > 9.1 | 0 | 0.01 | High | MCR |
| KT-13 | Wilms | Cisplatin | 18.6 | <0.001 | 1.7 | >4 | 0.29 | Low | PD2 |
| KT-13 | Wilms | M6620 | 10.6 | 0.595 | 1 | >4 | 0.97 | Low | PD1 |
| KT-13 | Wilms | Combo | 19.9 | <0.001 | 1.9 | >4 | 0.28 | Low | PD2 |
| KT-5* | Wilms | Cisplatin | 45.7 | <0.001 | 2.7 | >4 | 0.27 | Int | PD2 |
| KT-5* | Wilms | M6620 | 17.5 | 0.309 | 1 | >4 | 0.88 | Low | PD1 |
| KT-5* | Wilms | Combo | > EP | <0.001 | > 5.3 | 3.2 | 0.06 | Int | CR |
| SK-NEP-1 | Ewing | Cisplatin | > EP | <0.001 | > 9.0 | 0 | 0.01 | High | MCR |
| SK-NEP-1 | Ewing | M6620 | 13.4 | 0.016 | 1.3 | >4 | 0.78 | Low | PD1 |
| SK-NEP-1 | Ewing | Combo | > EP | <0.001 | > 9.0 | 0 | 0.01 | High | MCR |
| EW5 | Ewing | Cisplatin | 56.9 | <0.001 | 1.8 | >4 | 0.08 | Int | CR |
| EW5 | Ewing | M6620 | 15.3 | 0.495 | 0.5 | >4 | 1.06 | Low | PD1 |
| EW5 | Ewing | Combo | 39.5 | <0.001 | 1.2 | >4 | 0.2 | Low | CR |
| EW8 | Ewing | Cisplatin | 12.8 | 0.185 | 0.9 | >4 | 0.98 | Low | PD1 |
| EW8 | Ewing | M6620 | 12.2 | 0.605 | 0.9 | >4 | 1.01 | Low | PD1 |
| EW8 | Ewing | Combo | 12.5 | 0.714 | 0.9 | >4 | 1 | Low | PD1 |
| TC-71 | Ewing | Cisplatin | 16.1 | 0.002 | 1.3 | >4 | 0.53 | Low | PD1 |
| TC-71 | Ewing | M6620 | 11.2 | 0.927 | 0.9 | >4 | 1.02 | Low | PD1 |
| TC-71 | Ewing | Combo | 19.5 | <0.001 | 1.5 | >4 | 0.41 | Low | PD1 |
| Rh30 | Alveolar RMS | Cisplatin | 28.5 | 0.001 | 1.3 | >4 | 0.4 | Low | PD1 |
| Rh30 | Alveolar RMS | M6620 | 14.5 | 0.731 | 0.6 | >4 | 1.42 | Low | PD1 |
| Rh30 | Alveolar RMS | Combo | 28.2 | 0.005 | 1.3 | >4 | 0.36 | Low | PD1 |
| Rh30R | Alveolar RMS | Cisplatin | 19.9 | 0.015 | 1.4 | >4 | 0.68 | Low | PD1 |
| Rh30R | Alveolar RMS | M6620 | 14.3 | 0.99 | 1 | >4 | 0.94 | Low | PD1 |
| Rh30R | Alveolar RMS | Combo | 19.9 | 0.029 | 1.4 | >4 | 0.72 | Low | PD1 |
| Rh41 | Alveolar RMS | Cisplatin | 15.1 | <0.001 | 2.2 | >4 | 0.55 | Int | PD2 |
| Rh41 | Alveolar RMS | M6620 | 7.6 | 0.094 | 1.1 | >4 | 0.88 | Low | PD1 |
| Rh41 | Alveolar RMS | Combo | 20.1 | <0.001 | 3 | >4 | 0.44 | Int | PD2 |
| Rh18 | Embryonal RMS | Cisplatin | 22.8 | 0.023 | 1.6 | >4 | 0.53 | Low | PD2 |
| Rh18 | Embryonal RMS | M6620 | 15.8 | 0.831 | 1.1 | >4 | 0.93 | Low | PD1 |
| Rh18 | Embryonal RMS | Combo | 20.6 | 0.03 | 1.5 | >4 | 0.66 | Low | PD1 |
| BT-50 | Medulloblastoma | Cisplatin | 38.1 | 0.754 | 0.8 | >4 | 0.86 | Low | PD1 |
| BT-50 | Medulloblastoma | M6620 | 40 | 0.368 | 0.9 | >4 | 0.94 | Low | PD1 |
| BT-50 | Medulloblastoma | Combo | 42 | 0.101 | 0.9 | >4 | 0.85 | Low | PD1 |
| GBM2 | Glioblastoma | Cisplatin | 17.4 | <0.001 | 1.7 | >4 | 0.46 | Low | PD2 |
| GBM2 | Glioblastoma | M6620 | 9.2 | 0.619 | 0.9 | >4 | 1.13 | Low | PD1 |
| GBM2 | Glioblastoma | Combo | 14.3 | 0.002 | 1.4 | >4 | 0.61 | Low | PD1 |
| D645 | Glioblastoma | Cisplatin | 15.8 | 0.006 | 1.2 | >4 | 0.75 | Low | PD1 |
| D645 | Glioblastoma | M6620 | 12.9 | 0.637 | 1 | >4 | 0.97 | Low | PD1 |
| D645 | Glioblastoma | Combo | 13.5 | 0.77 | 1 | >4 | 0.93 | Low | PD1 |
| D456 | Glioblastoma | Cisplatin | 12.5 | <0.001 | 1.4 | >4 | 0.75 | Low | PD1 |
| D456 | Glioblastoma | M6620 | 10.4 | 0.146 | 1.2 | >4 | 0.85 | Low | PD1 |
| D456 | Glioblastoma | Combo | 13 | 0.002 | 1.5 | >4 | 0.59 | Low | PD1 |
| D212 | Glioblastoma | Cisplatin | 21.6 | 0.005 | 1.4 | >4 | 0.74 | Low | PD1 |
| D212 | Glioblastoma | M6620 | 13.5 | 0.783 | 0.9 | >4 | 1.11 | Low | PD1 |
| D212 | Glioblastoma | Combo | 21.7 | 0.002 | 1.4 | >4 | 0.65 | Low | PD1 |
| NB-1691 | Neuroblastoma | Cisplatin | 10.2 | 0.002 | 1.5 | >4 | 0.8 | Low | PD1 |
| NB-1691 | Neuroblastoma | M6620 | 11.2 | 0.002 | 1.6 | >4 | 0.8 | Low | PD2 |
| NB-1691 | Neuroblastoma | Combo | 12.2 | 0.012 | 1.8 | >4 | 0.69 | Low | PD2 |
| NB-EBc1* | Neuroblastoma | Cisplatin | 7.3 | 0.095 | 1.1 | >4 | 0.81 | Low | PD1 |
| NB-EBc1* | Neuroblastoma | M6620 | 9.9 | 0.02 | 1.5 | >4 | 0.72 | Low | PD1 |
| NB-EBc1* | Neuroblastoma | Combo | 12.7 | <0.001 | 1.9 | >4 | 0.47 | Low | PD2 |
| NB-1643 | Neuroblastoma | Cisplatin | 9 | 0.065 | 1.1 | >4 | 0.82 | Low | PD1 |
| NB-1643 | Neuroblastoma | M6620 | 8.6 | 0.369 | 1.1 | >4 | 0.99 | Low | PD1 |
| NB-1643 | Neuroblastoma | Combo | 8.9 | 0.232 | 1.1 | >4 | 0.8 | Low | PD1 |
| OS-2 | Osteosarcoma | Cisplatin | 44.4 | 0.073 | 1.1 | >4 | 0.3 | Low | PD1 |
| OS-2 | Osteosarcoma | M6620 | 26 | 0.259 | 0.7 | >4 | 1.13 | Low | PD1 |
| OS-2 | Osteosarcoma | Combo | 52.4 | 0.018 | 1.3 | >4 | 0.4 | Low | PD1 |
| OS-17 | Osteosarcoma | Cisplatin | 17 | <0.001 | 1.5 | >4 | 0.67 | Low | PD1 |
| OS-17 | Osteosarcoma | M6620 | 17.6 | 0.009 | 1.5 | >4 | 0.72 | Low | PD2 |
| OS-17 | Osteosarcoma | Combo | 17.5 | <0.001 | 1.5 | >4 | 0.64 | Low | PD1 |
| OS-9* | Osteosarcoma | Cisplatin | 39.6 | 0.869 | 1 | >4 | 0.98 | Low | PD1 |
| OS-9* | Osteosarcoma | M6620 | 39.1 | 0.521 | 1 | >4 | 0.84 | Low | PD1 |
| OS-9* | Osteosarcoma | Combo | 69.5 | 0.001 | 1.7 | >4 | 0.54 | Low | PD2 |